List of references supporting the assessment of *Serenoa repens* (W. Bartram) Small, fructus

Final

The European Medicines Agency acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.


Argirović A, Argirović D. [Does the addition of *Serenoa repens* to tamsulosin improve its therapeutical efficacy in benign prostatic hyperplasia?]. *Vojnosanit Pregl* 2013, 70(12):1091-1096 [Serbian]


Casasosa C, Cosci di Coscio M, Fratta M. Lack of effects of a liposterolic extract of *Serenoa repens* on plasma levels of testosterone, follicle-stimulating hormone, and luteinizing hormone. *Clin Ther* 1988, 10(5):585-588


De Combarieu E, Martinelli EM, Pace R, Sardone N. Metabolomics study of Saw palmetto extracts based on 1H NMR spectroscopy. *Fitoterapia* 2015, 102:56-60


De la Taille A. Therapeutic approach. The Importance of controlling prostatic inflammation. *Uropean Urology* Supplements 2013, 12:116-122


Delfosse M. Drogues végétales et plantes médicinales. APB, Brussels 1998, 356-357


ESCOP Monographs 2nd ed. *Serenoa repens* fructus (Sabal fructus). Thieme Verlag, Stuttgart 2003, 477-486


Habib FK, Wyllie MG. Not all brands are created equal: a comparison of selected components of different brands of *Serenoa repens* extract. *Prostate Cancer and Prostatic Dis* 2004, 7(3):195-200


Hiermann A. The contents of sabal fruits and testing of their anti-inflammatory effect. *Arch Pharm (Weinheim)* 1989, 322(2):111-114


List of references supporting the assessment of *Serenoa repens* (W. Bartram) Small, fructus

EMA/HMPC/280080/2013

---


Loew D, Habs M, Klimm H-D, Trunzler G. Phytopharmaka Report. 2te Auflage. Steinkopff Darmstadt 1999, 174-190


Roehrborn CG. Definition of at-risk patients; baseline variables. *BJU Int* 2006, 97 Suppl 2: 7-11


Van Hellemont J. Fytotherapeutisch Compendium. APB, Brussels 1985, 534-535


Weisser H, Behnke B, Helpap B, Bach D, Krieg M. Enzyme activities in tissue of human benign prostatic hyperplasia after three months’ treatment with the Sabal serrulata extract IDS 89 (Strogen®) or placebo. Eur Urol 1997, 31(1):97-101


References assessed but not sighted in the assessment report
